Dana-Farber Cancer Institute: Carcinoma, Ovarian Epithelial trials
The registry lists 10 Carcinoma, Ovarian Epithelial studies with Dana-Farber Cancer Institute as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 3Phase 2 3No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related FatigueCompletedNCT04525183Not applicableResults posted
- Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian CancerCompletedNCT03364673Not applicableResults posted
- Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian CancerTerminatedNCT00910000Phase 1/2Results posted
- Ribociclib + PDR001 in Breast Cancer and Ovarian CancerTerminatedNCT03294694Phase 1
- Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by CuldocentesisTerminatedNCT02441140Not applicable
- Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot InterventionCompletedNCT02287519Not applicable
- Olaparib for Patients With Recurrent BRCA Deficient Ovarian CancerWithdrawnNCT01661868Phase 2
- Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian CancerCompletedNCT01623349Phase 1
- Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual FunctionCompletedNCT00525460
- Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian CancerCompletedNCT00230542Phase 2